← back to search

Reuven Agami

University of Michigan–Ann Arbor · US
Area of research
Molecular Biology · Cancer Research
Research interest
Research focused on Serine and Library science, with related work in Translational frameshift, Translation (biology), Enhancer. Notable publications include 'eRNAs Are Required for p53-Dependent Enhancer Activity and Gene Transcription', 'Anti-tumour immunity induces aberrant peptide presentation in melanoma', and 'Tryptophan depletion results in tryptophan-to-phenylalanine substitutants'.
h-index
citations
1,487
works
20
NIH funding
primary concept
email

Recent publications

Upstream open reading frame translation enhances immunogenic peptide presentation in mitotically arrested cancer cells
Nature Communications 2025cited by 3position: middledoi
Upstream open reading frame translation enhances immunogenic peptide presentation in mitotically arrested cancer cells
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 1position: middledoi
DNA damage induces p53-independent apoptosis through ribosome stalling
Science 2024cited by 117position: middledoi
Arginine deprivation enriches lung cancer proteomes with cysteine by inducing arginine-to-cysteine substitutants
Molecular Cell 2024cited by 22position: lastdoi
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
Cancer Cell 2024cited by 16position: middledoi
Gene and protein sequence features augment HLA class I ligand predictions
Cell Reports 2024cited by 4position: middledoi
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
The Journal of Experimental Medicine 2023cited by 27position: middledoi
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Nature 2022cited by 133position: lastdoi
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
Nature Communications 2022cited by 44position: middledoi
Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors
Oncogene 2022cited by 15position: lastdoi
Oncogene-dependent sloppiness in mRNA translation
Molecular Cell 2021cited by 55position: lastdoi
A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis
Genome biology 2021cited by 24position: lastdoi
Anti-tumour immunity induces aberrant peptide presentation in melanoma
Nature 2020cited by 148position: lastdoi
Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells
Nature Communications 2019cited by 105position: middledoi
SLC1A3 contributes to L‐asparaginase resistance in solid tumors
The EMBO Journal 2019cited by 72position: lastdoi
A fragment-like approach to PYCR1 inhibition
Bioorganic & Medicinal Chemistry Letters 2019cited by 39position: lastdoi
Micro-RNA 124 Regulates Homologous Recombination Protein RAD51 and Sensitizes Glioblastoma Cells to Radiation
International Journal of Radiation Oncology*Biology*Physics 2018cited by 1position: middledoi
Long non-coding RNAs in metastasis
Cancer and Metastasis Reviews 2017cited by 70position: lastdoi
Myc coordinates transcription and translation to enhance transformation and suppress invasiveness
EMBO Reports 2015cited by 60position: lastdoi
eRNAs Are Required for p53-Dependent Enhancer Activity and Gene Transcription
Molecular Cell 2012cited by 531position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Fabricio Loayza‐Puch · German Cancer Research Center6 papers (2015–2025) · 6 papers (2019–2024)Onno B. Bleijerveld · Utrecht University6 papers (2015–2024)Esther A. Zaal · Utrecht University5 papers (2019–2024) · 5 papers (2022–2025)Maarten Altelaar · Utrecht University5 papers (2015–2023)Celia R. Berkers · Utrecht University5 papers (2019–2024) · 4 papers (2022–2025) · 4 papers (2019–2022) · 4 papers (2021–2025)Olaf van Tellingen · Utrecht University3 papers (2019–2022) · 3 papers (2012–2021)Rui Lopes · Novartis (Switzerland)2 papers (2015–2021)Domenica Lovecchio · Institut Pasteur2 papers (2022–2022) · 2 papers (2015–2021)Angelika B. Riemer · German Cancer Research Center2 papers (2025–2025)Jianhui Sun · Soochow University2 papers (2019–2019)Fiona Megan Tilghman · German Cancer Research Center2 papers (2025–2025)Hanan Sakeer · German Cancer Research Center2 papers (2025–2025)Ton N. Schumacher · Oncode Institute2 papers (2024–2024)